AcadeMab Biomedical

Focus: AcadeMab Biomedical is a Taiwan-based biotech company founded in 2020 specializing in antibody and mRNA drug development, with a focus on gene therapy. The company is early-stage with minimal public commercial footprint.

Gene Therapy

Profile data last refreshed 4d ago · AI intelligence enriched 2w ago

Open Jobs

About AcadeMab Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow AcadeMab Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RBC-SCAN

Diagnostic imaging (red blood cell imaging)

LOE Approaching

Legacy NDA product with approaching loss of exclusivity; appears to be a non-core asset with minimal revenue contribution.

Products & Portfolio (1)

Help build intelligence for AcadeMab Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a young biotech (founded 2020) with focused expertise in high-value modalities (antibodies and mRNA)
Gene therapy therapeutic area offers exposure to cutting-edge science with significant unmet medical need and venture interest
Taiwan location provides access to growing Asia-Pacific biotech hub with lower cost of living and emerging innovation ecosystem

Watch Out For

Company shows zero active clinical trials and no disclosed pipeline programs, signaling very early-stage development with extended timelines to value creation
No open job postings (activeJobCount = 0) and undisclosed employee count, headcount, and funding—raising questions about hiring plans and financial runway
Single marketed product (RBC-SCAN) is a legacy radiopharmaceutical kit approaching loss of exclusivity with no disclosed revenue, suggesting minimal current business foundation

Generated by Claude from AcadeMab Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Pipeline & Clinical Trials

AM-928

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05687682Safety of AM-928 Infusion in Advanced Solid Tumors

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 1 approved product, 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

LOE Approaching1 (100%)

1 total products

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline